Overexpression of GYS1, MIF, and MYC is associated with adverse outcome and poor response to azacitidine in myelodysplastic syndromes and acute myeloid leukemia

Clin Lymphoma Myeloma Leuk. 2015 Apr;15(4):236-44. doi: 10.1016/j.clml.2014.10.003. Epub 2014 Oct 23.

Abstract

Background: The prognosis of myelodysplastic syndromes (MDS) and acute myeloid leukaemia (AML) is very heterogeneous.

Patients and methods: We analyzed the prognostic value of several genes in a cohort of 85 MDS and AML patients.

Results: Overexpression of glycogen synthase 1 and macrophage migration inhibitory factor genes had an adverse outcome in multivariate analysis (P = .003 and P < .001, respectively). Furthermore, the higher expression of myelocytomatosis oncogene was associated with a lower response to azacitidine (P = .03).

Conclusion: In the current study we identified a specific gene expression profile as prognostic factors for response to azacitidine and survival in MDS and AML.

Keywords: Acute leukemia; Azacitidine; Gene expression; Myelodysplastic syndromes; Prognosis.

MeSH terms

  • Aged
  • Aged, 80 and over
  • Antimetabolites, Antineoplastic / therapeutic use
  • Azacitidine / therapeutic use
  • Gene Expression Profiling
  • Gene Expression*
  • Genes, myc*
  • Glycogen Synthase / genetics*
  • Humans
  • Hypoxia / genetics
  • Intramolecular Oxidoreductases / genetics*
  • Leukemia, Myeloid, Acute / diagnosis
  • Leukemia, Myeloid, Acute / drug therapy*
  • Leukemia, Myeloid, Acute / genetics*
  • Leukemia, Myeloid, Acute / mortality
  • Macrophage Migration-Inhibitory Factors / genetics*
  • Middle Aged
  • Myelodysplastic Syndromes / diagnosis
  • Myelodysplastic Syndromes / drug therapy*
  • Myelodysplastic Syndromes / genetics*
  • Myelodysplastic Syndromes / mortality
  • Prognosis
  • Survival Analysis
  • Treatment Outcome

Substances

  • Antimetabolites, Antineoplastic
  • Macrophage Migration-Inhibitory Factors
  • Glycogen Synthase
  • Intramolecular Oxidoreductases
  • MIF protein, human
  • Azacitidine